<DOC>
	<DOCNO>NCT00352911</DOCNO>
	<brief_summary>The objective study determine whether mifepristone ( VGX-410 ) anti-HIV-1 activity dose either 300 mg 600 mg per day oral administration 14 day dose level .</brief_summary>
	<brief_title>Antiviral Activity Safety Mifepristone 2 Doses HIV-1 Infected Subjects</brief_title>
	<detailed_description>VT004 double-blind , randomize , placebo-controlled Phase II study two dos orally administer mifepristone ( VGX-410 ) ( 300 600 mg ) take twice daily ( BID ) dosage ( 150mg BID 300mg BID ) dose-escalating fashion 14 day dose level determine antiviral activity safety HIV-1-infected participant . At entry , 18 subject randomize 5:1 fashion ( 15 active drug : 3 placebo ) receive escalate dos VGX-410 match placebo . Patients randomize receive 300 mg ( 150 mg BID dose ) VGX-410 match placebo 14 day . In patient complete dose without significant safety concern side effect , dose increase 600 mg ( 300 mg BID dose ) match placebo 14 day . Patients must meet inclusion/exclusion criterion list see weekly basis study personnel study drug . Patients must return ~ one month finish study therapy examination safety lab .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>HIV1 infection CD4 cell count &gt; 200 Plasma HIV1 RNA &gt; 2000 copies/mL receive antiretroviral therapy within 16 week prior entry Absolute neutrophil count &gt; 750/mm3 Hemoglobin &gt; 10 g/dL Platelet count &gt; 100,000 mm3 Creatinine &lt; 2 X upper limit normal [ ULN ] ( fast ) AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase &lt; 2 X ULN Total bilirubin &lt; 2.5 X ULN Albumin &gt; 3 g/dL Serum lipase &lt; 1.5 X ULN Thyroid stimulate hormone ( TSH ) within normal limit Plasma cortisol &gt; 20 mcg/dL , 30 minute cosyntropin administration Negative pregnancy test willing use effective birth control study Karnofsky performance score &gt; 80 within 30 day prior study entry Men woman &gt; = 18 year age Receipt antiretroviral treatment within 16 week prior study entry Chronic adrenal failure , adrenal insufficiency , personal family history autoimmune endocrine disease , history active hepatitis B C , current treatment hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) Presence diabetes mellitus Pregnancy within 90 day prior study entry breastfeed Dysfunctional uterine bleed within 12 month prior study entry Any current hormonal contraception intrauterine device ( IUD ) use Use drug inhibitor inducer metabolism cytochrome P450 3A4 within 7 day prior study entry Use systemic corticosteroid hormonal agent within 90 day prior study entry Use immunomodulator , HIV vaccine , investigational therapy within 90 day prior study entry Any vaccination within 30 day prior study entry Use systemic cytotoxic chemotherapy within 90 day prior study entry History allergy mifepristone formulation Active drug alcohol use Serious illness require systemic treatment and/or hospitalization least 14 day prior study entry Weight &lt; 40 kg 88 lb . within 90 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>HIV-1</keyword>
</DOC>